Research
Hormonal
Pharmacotherapy for obesity is indicated for patients with BMI >= 30 kg/m2 or >= 27 kg/m2 with comorbidities, and efficacy is defined as >= 5% weight loss after 3 months.
If your BMI is 30+ (or 27+ with health issues), ask about medication. It's not a failure; it's a tool. If you don't lose at least 5% in 3 months, the drug isn't working for you.
GoodConditionalHIGH confidence
In accordance with practice recommendations from international societies, pharmacotherapy may be offered to patients with BMI ≥ 30 kg/m2 or ≥27 kg/m2 with comorbidities... An anti-obesity treatment is considered effective if 5% or more weight loss is achieved after 3 months of drug initiation.
Why this rating
Consensus based on FDA/EMA approvals and international guidelines.
Source
Diagnosis and Management of Obesity: A Joint Statement by Practicing Endocrinologists
Maya Barake et al. · Journal of Diabetes Mellitus · 2023
DOI 10.4236/jdm.2023.132008
clinical_guidelineCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle intervention (diet, physical activity, behavioral changes) is the cornerstone of obesity treatment and should be initiated in all patients, regardless of whether pharmacotherapy or surgery is added.Strong
- Obesity is a primary chronic disease driven largely by genetic predisposition, amplified by caloric intake and decreased energy expenditure, requiring recognition as a disease for proper insurance coverage and management.Good
- Bariatric surgery is indicated for patients with BMI >= 40 kg/m2 or >= 35 kg/m2 with comorbidities, and offers benefits beyond weight loss including glycemic control and improved life expectancy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →